Design, synthesis and biological evaluation of novel quinazoline derivatives as potential antitumor agents: Molecular docking study

被引：252

作者：

El-Azab, Adel S. ^{[1
]}

Al-Omar, Mohamed A. ^{[1
]}

Abdel-Aziz, Alaa A. -M. ^{[1
]}

Abdel-Aziz, Naglaa I. ^{[2
]}

El-Sayed, Magda A. -A. ^{[3
]}

Aleisa, Abdulaziz M. ^{[4
]}

Sayed-Ahmed, Mohamed M. ^{[4
]}

Abdel-Hamide, Sami G. ^{[5
]}

机构：

[1] King Saud Univ, Coll Pharm, Dept Pharmaceut Chem, Riyadh 11451, Saudi Arabia

[2] Univ Mansoura, Fac Pharm, Dept Med Chem, Mansoura 35516, Egypt

[3] Univ Mansoura, Fac Pharm, Dept Pharmaceut Organ Chem, Mansoura 35516, Egypt

[4] King Saud Univ, Coll Pharm, Dept Pharmacol, Riyadh 11451, Saudi Arabia

[5] Al Kharj Univ, Dept Pharmaceut Chem, Coll Pharm, Al Kharj, Saudi Arabia

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2010年 / 45卷 / 09期

关键词：

Synthesis; Quinazoline; Antitumor; Drug-likeness; Molecular docking; GROWTH; LAPATINIB; CYTOTOXICITY; INHIBITORS; GW572016; CANCER; SERIES;

D O I：

10.1016/j.ejmech.2010.06.013

中图分类号：

R914 [药物化学];

学科分类号：

100705 [微生物与生化药学];

摘要：

Novel derivatives of quinazoline (1-27) have been synthesized and tested for their antitumor activity against three tumor cell lines among these cell lines the human breast carcinoma cell line (MCF-7) in which EGFR is highly expressed. All tested compounds showed potent and selective activity against breast cancer (MCF-7) with IC50 range of 3.35-6.81 mu g/ml. With regarding broad-spectrum activity compounds 5, 9, 15, 18 and 20 exploited potent antitumor against human liver cell line (HEPG2), human breast cell line (MCF-7) and human cervix cell line (HELA) with IC50 range of 3.35-5.59 mu g/ml. Virtual screening was carried out through docking the designed compounds into the ATP binding site of epidermal growth factor receptor (EGFR) to predict if these compounds have analogous binding mode to the EGFR inhibitors. (C) 2010 Elsevier Masson SAS. All rights reserved.

引用

页码：4188 / 4198

页数：11

共 39 条

[1]

Novel and versatile methodology for synthesis of cyclic imides and evaluation of their cytotoxic, DNA binding, apoptotic inducing activities and molecular modeling study [J].

Abdel-Aziz, Alaa A. -M. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2007, 42 (05) :614-626

[2]

Design, synthesis and in vitro antitumor activity of 4-aminoquinoline and 4-aminoquinazoline derivatives targeting EGFR tyrosine kinase [J].

Abouzid, Khaled ;

Shouman, Samia .

BIOORGANIC & MEDICINAL CHEMISTRY, 2008, 16 (16) :7543-7551

[3]

Substituted quinazolines, part 3. Synthesis, in vitro antitumor activity and molecular modeling study of certain 2-thieno-4(3H)-quinazolinone analogs [J].

Al-Obaid, Abdulrahman M. ;

Abdel-Hamide, Sami G. ;

El-Kashef, Hassan A. ;

Abdel-Aziz, Alaa A. -M. ;

El-Azab, Adel S. ;

Al-Khamees, Hamad A. ;

El-Subbagh, Hussein I. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2009, 44 (06) :2379-2391

[4]

Non-classical antifolates. Part 2: Synthesis, biological evaluation, and molecular modeling study of some new 2,6-substituted-quinazolin-4-ones [J].

Al-Omary, Fatmah A. M. ;

Abou-zeid, Laila A. ;

Nagi, Mahmoud N. ;

Habib, El-Sayed E. ;

Abdel-Aziz, Alaa A-M. ;

El-Azab, Adel S. ;

Abdel-Hamide, Sami G. ;

Al-Omar, Mohamed A. ;

Al-Obaid, Abdulrahman M. ;

El-Subbagh, Hussein I. .

BIOORGANIC & MEDICINAL CHEMISTRY, 2010, 18 (08) :2849-2863

[5]

Synthesis, dihydrofolate reductase inhibition, antitumor testing, and molecular modeling study of some new 4(3H)-quinazolinone analogs [J].

Al-Rashood, Sarah T. ;

Aboldahab, Ihsan A. ;

Nagi, Mahmoud N. ;

Abouzeid, Laila A. ;

Abdel-Aziz, Alaa A. M. ;

Abdel-hamide, Sarni G. ;

Youssef, Khairia M. ;

Al-Obaid, Abdulrahman M. ;

EI-Subbagh, Hussein I. .

BIOORGANIC & MEDICINAL CHEMISTRY, 2006, 14 (24) :8608-8621

[6]

Tyrosine kinase inhibitors-ZD1839 (Iressa) [J].

Arteaga, CL ;

Johnson, DH .

CURRENT OPINION IN ONCOLOGY, 2001, 13 (06) :491-498

[7]

Studies leading to the identification of ZD1839 (Iressa™):: An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer [J].

Barker, AJ ;

Gibson, KH ;

Grundy, W ;

Godfrey, AA ;

Barlow, JJ ;

Healy, MP ;

Woodburn, JR ;

Ashton, SE ;

Curry, BJ ;

Scarlett, L ;

Henthorn, L ;

Richards, L .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1911-1914

[8]

Getitinib (ZD1839, Iressa®) in non-small-cell lung cancer:: a review of clinical trials from a daily practice perspective [J].

Barlési, F ;

Tchouhadjian, C ;

Doddoli, C ;

Villani, P ;

Greillier, L ;

Kleisbauer, JP ;

Thomas, P ;

Astoul, P .

FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2005, 19 (03) :385-393

[9]

Bridges AJ, 1999, CURR MED CHEM, V6, P825

[10]

Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas [J].

Burris, HA ;

Hurwitz, HI ;

Dees, EC ;

Dowlati, A ;

Blackwell, KL ;

O'Neil, B ;

Marcom, PK ;

Ellis, MJ ;

Overmoyer, B ;

Jones, SF ;

Harris, JL ;

Smith, DA ;

Koch, KM ;

Stead, A ;

Mangum, S ;

Spector, NL .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (23) :5305-5313

← 1 2 3 4 →